שולי רווח נקי OncoCyte Inc (OCX)

High capacity utilization of diagnostic centers and equipment modernization ensure a steady flow of tests for OncoCyte Corporation (OCX). Growth scales through the sale of Determa kit licenses, eliminating the costs associated with new laboratories. The integration of these tests into clinical practice drives the trend reflected in the net profit margin chart, where the value -1516.10 represents the issuer's current profit-to-revenue ratio.
פילוחים אנליטיים ודוחות נתונים של חברת OncoCyte Corporation (OCX)

Determa high-precision molecular tests determine the commercial effectiveness of OncoCyte Corporation (OCX) in lung cancer diagnostics. This net profit margin metric measures the portion of net income in every dollar of revenue, reflecting the ultimate efficiency of the operating model. Analyzing this trend helps avoid freezing capital in overheated assets during a cycle shift. The investor sees the business's real ability to generate income without quarterly delays. This net profit margin chart reveals hidden drawdown risks.